Pacibekitug, a long-acting monoclonal antibody targeting interleukin-6, produced sustained reductions in inflammatory biomarkers among chronic kidney disease patients at high inflammatory risk, according to phase II TRANQUILITY trial results presented at the ESC Congress 2026. The findings mark an important step in addressing residual cardiovascular risk driven by inflammation rather than traditional factors like cholesterol or smoking.
TRANQUILITY Trial Results and Interleukin-6 Targeting
Traditional risk factors such as hypertension, smoking, diabetes, high cholesterol levels, and obesity account for roughly half of the global burden of cardiovascular disease, according to background data presented at the conference. The remaining risk is increasingly tied to inflammation. Approximately 30% of patients with atherosclerotic cardiovascular disease and 40% of those with concomitant chronic kidney disease remain at high inflammatory risk despite standard therapies, as measured by elevated high-sensitivity C-reactive protein (hs-CRP) levels.
According to Principal Investigator Professor Deepak Bhatt from the Icahn School of Medicine at Mount Sinai in New York City, a growing body of genetic, epidemiological, and clinical evidence points to interleukin-6 (IL-6) as a key inflammatory mediator linked to cardiovascular risk.
Did you know? Traditional lifestyle factors like diet and smoking only explain about half of all global cardiovascular disease cases. Chronic inflammation accounts for a significant portion of the remaining risk, prompting new trials targeting inflammatory pathways like IL-6.
Dose-Dependent Reductions in Inflammatory Biomarkers
Pacibekitug treatment yielded dose-dependent decreases in hs-CRP by day 30, which remained sustained through day 180. Data presented at the session showed the median time-averaged change from baseline in hs-CRP through day 180 was a 7% increase with placebo, compared to a 76% reduction with pacibekitug 25 mg every 90 days, an 85% reduction with pacibekitug 50 mg every 90 days, and an 89% reduction with pacibekitug 15 mg every 30 days. All comparisons against placebo reached statistical significance.
Beyond hs-CRP, the trial observed sustained reductions in other inflammatory markers, fibrinogen, and lipoprotein(a) across all pacibekitug dosing groups compared to placebo.
| Treatment Group | Dosing Schedule | Median Time-Averaged Change in hs-CRP (Day 180) |
|---|---|---|
| Placebo | Standard intervals | +7% |
| Pacibekitug 25 mg | Every 90 days | -76% |
| Pacibekitug 50 mg | Every 90 days | -85% |
| Pacibekitug 15 mg | Every 30 days | -89% |
Next Steps for Phase III Cardiovascular Outcomes Trials
The trial results demonstrate that the IL-6 pathway can be durably suppressed using infrequent dosing regimens without introducing new safety signals, according to Professor Bhatt.
The logical next step involves advancing pacibekitug into a larger, longer-term phase III clinical trial. Such a study would definitively test whether suppressing IL-6 improves actual cardiovascular outcomes for high-risk patients with chronic kidney disease.
Frequently Asked Questions
What is pacibekitug?
Pacibekitug is a long-acting monoclonal antibody designed to target and inhibit interleukin-6, a key mediator of inflammation linked to cardiovascular disease.
What did the TRANQUILITY trial measure?
The phase II TRANQUILITY trial evaluated the safety and efficacy of pacibekitug in reducing inflammatory biomarkers, specifically high-sensitivity C-reactive protein (hs-CRP), in patients with chronic kidney disease.
Were there any safety concerns identified with pacibekitug?
What is the next phase of research for pacibekitug?
Investigators plan to conduct larger, longer-term phase III clinical trials to assess whether the biomarker reductions observed in the TRANQUILITY trial translate into improved cardiovascular outcomes.
Want to stay updated on the latest cardiovascular clinical trials and cardiology research? Subscribe to our newsletter or leave a comment below to join the discussion.
Worth a look